U.K. Beverage Stock News

AstraZeneca (LSE:AZN) has been quietly reshaping its growth story, and the latest trading action reflects investors weighing that shift against a share price that is already up about 31% over the past year. See our latest analysis for AstraZeneca. That momentum has cooled a little in recent weeks, with the 30 day share price return slightly negative, even as a strong 90 day share price return and robust five year total shareholder return suggest investors are still rewarding AstraZeneca’s...

Ideally, your overall portfolio should beat the market average. But every investor is virtually certain to have both...

Key Insights Given the large stake in the stock by institutions, RELX's stock price might be vulnerable to their...

Finding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key...

Most readers would already be aware that Bellway's (LON:BWY) stock increased significantly by 13% over the past three...

The board of Cohort plc ( LON:CHRT ) has announced that it will pay a dividend on the 17th of February, with investors...

If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. Typically, we'll...

Hercules Plc ( LON:HERC ) shareholders have had their patience rewarded with a 26% share price jump in the last month...

There wouldn't be many who think Transense Technologies plc's ( LON:TRT ) price-to-earnings (or "P/E") ratio of 14.9x...

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...

Haydale Graphene Industries plc ( LON:HAYD ) is possibly approaching a major achievement in its business, so we would...

CEPS PLC's ( LON:CEPS ) price-to-earnings (or "P/E") ratio of 18x might make it look like a sell right now compared to...

When close to half the companies in the United Kingdom have price-to-earnings ratios (or "P/E's") below 15x, you may...

Cranswick plc ( LON:CWK ) shareholders might have a reason to worry after multiple insiders sold their shares over the...

Key Insights Given the large stake in the stock by institutions, InterContinental Hotels Group's stock price might be...

By buying an index fund, you can roughly match the market return with ease. But if you pick the right individual...

Despite an already strong run, AltynGold plc ( LON:ALTN ) shares have been powering on, with a gain of 26% in the last...

Kromek Group (LON:KMK) has had a great run on the share market with its stock up by a significant 59% over the last...

Whitbread (LON:WTB) has had a rough three months with its share price down 24%. However, the company's fundamentals...

The United Kingdom's FTSE 100 index has recently experienced a downturn, influenced by weak trade data from China, which continues to struggle with its post-pandemic recovery. Despite these broader market challenges, there remains potential within the realm of penny stocks—an area often overlooked but still relevant for investors seeking opportunities in smaller or newer companies. These stocks can offer both affordability and growth potential when backed by strong financials, making them an...

Weir Group (LON:WEIR) has had a great run on the share market with its stock up by a significant 13% over the last...

If you are wondering whether GSK still offers good value after its recent strong run, or if you have already missed the opportunity, this breakdown will help you assess whether the current price is reasonable or if it may still offer upside. Despite a flat week and month, with returns of around -0.3% over 7 days and -0.2% over 30 days, GSK is still showing a substantial year-to-date gain of 33.7% and a 42.5% return over the past year, which suggests that sentiment has shifted decisively in...

Wondering if Rio Tinto Group is still good value after its recent run, or if you are late to the party? This breakdown will help you figure out whether the current price makes sense or is quietly offering upside. Over the last week the stock is up 3.5%, 6.8% over the past month, and roughly 19.3% year to date, building on a 20.7% 1-year gain and a 53.0% rise over 5 years that has clearly rewarded patient holders. Recent moves have been driven by shifting expectations around global steel...

Shell (LSE:SHEL) has slipped about 8% over the past month even as its long term track record and cash generation remain solid, setting up an interesting entry point for patient income focused investors. See our latest analysis for Shell. At around $27.07, Shell’s recent 30 day share price pullback sits in contrast to its positive year to date share price return and strong multi year total shareholder returns. This suggests momentum has cooled rather than broken. If Shell’s reset has you...